Aster Capital Management DIFC Ltd Grows Holdings in IQVIA Holdings Inc. $IQV

Aster Capital Management DIFC Ltd increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 444.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,863 shares of the medical research company’s stock after buying an additional 11,318 shares during the period. IQVIA comprises approximately 1.4% of Aster Capital Management DIFC Ltd’s holdings, making the stock its 11th biggest holding. Aster Capital Management DIFC Ltd’s holdings in IQVIA were worth $3,125,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Abound Financial LLC bought a new stake in shares of IQVIA in the 4th quarter worth about $103,000. L2 Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth about $420,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of IQVIA in the 4th quarter worth about $379,000. Squarepoint Ops LLC increased its position in shares of IQVIA by 299.4% in the 4th quarter. Squarepoint Ops LLC now owns 6,127 shares of the medical research company’s stock worth $1,381,000 after purchasing an additional 4,593 shares during the last quarter. Finally, USS Investment Management Ltd increased its position in shares of IQVIA by 17.1% in the 4th quarter. USS Investment Management Ltd now owns 32,897 shares of the medical research company’s stock worth $7,418,000 after purchasing an additional 4,807 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IQV shares. HSBC set a $210.00 target price on shares of IQVIA in a research report on Wednesday, June 3rd. Morgan Stanley set a $225.00 price objective on shares of IQVIA in a research note on Thursday, May 7th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Evercore reiterated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Finally, Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Price Performance

NYSE IQV opened at $178.07 on Tuesday. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $29.72 billion, a price-to-earnings ratio of 22.07, a price-to-earnings-growth ratio of 1.56 and a beta of 1.21. The company has a 50-day moving average price of $173.65 and a two-hundred day moving average price of $193.06.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.